

Vital signs and biochemical data collection via “comestai” mHealth App, using non-contact photoplethysmography. Protocol for a clinical trial.

Gianvincenzo Zuccotti, Paolo Osvaldo Agnelli, Lucia Labati, Erika Cordaro, Davide Braghieri, Simone Balconi, Marco Xodo, Fabrizio Losurdo, Cesare Celeste Federico Berra, Roberto Franco Enrico Pedretti, Paolo Fiorina, Sergio Maria De Pasquale, Valeria Calcaterra

Submitted to: JMIR Research Protocols
on: August 09, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 23

 Figures 24

 Figure 1..... 25

 Figure 2..... 26

 Figure 3..... 27

CONSORT (or other) checklists..... 28

 CONSORT (or other) checklist 0..... 29

Vital signs and biochemical data collection via “comestai” mHealth App, using non-contact photoplethysmography. Protocol for a clinical trial.

Gianvincenzo Zuccotti^{1, 2} Prof Dr Med; Paolo Osvaldo Agnelli³ MA; Lucia Labati² MSc; Erika Cordaro² MSc; Davide Braghieri² MSc; Simone Balconi² MSc; Marco Xodo³ MA; Fabrizio Losurdo^{1, 4} MD; Cesare Celeste Federico Berra⁵ MD; Roberto Franco Enrico Pedretti⁶ MD; Paolo Fiorina^{1, 4, 7} Prof Dr Med; Sergio Maria De Pasquale³ MA; Valeria Calcaterra^{2, 8} MD

¹ Department of Biomedical and Clinical Science University of Milano Milano IT

² Pediatric Department Buzzi Children's Hospital Milano IT

³ Come Stai S.p.A Milano IT

⁴ Endocrine Diseases and Diabetology Unit Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco Milano IT

⁵ Diabetology and Endocrinology Unit Istituto di Ricovero e Cura a Carattere Scientifico MultiMedica Milano IT

⁶ Cardiac Rehabilitation Unit Istituto di Ricovero e Cura a Carattere Scientifico MultiMedica Milano IT

⁷ International Center for Type 1 Diabetes, Pediatric Clinical Research Center Romeo and Enrica Invernizzi University of Milano Milano IT

⁸ Pediatric and Adolescent Unit, Department of Internal Medicine University of Pavia Pavia IT

Corresponding Author:

Gianvincenzo Zuccotti Prof Dr Med

Pediatric Department
Buzzi Children's Hospital
Via Castelvetro n. 32
Milano
IT

Abstract

Background: Early detection of changes in vital signs typically correlates with faster identification of changes in the patient's health status and the escalation of care if necessary. Alterations in vital signs preceding clinical deterioration are well documented, and the early identification of preventable outcomes is crucial for timely intervention.

Objective: In this study, vital parameters (heart rate, respiratory rate, oxygen saturation, and blood pressure) will be measured using the 'comestai' application to confirm the accuracy of photoplethysmography (PPG) methods compared to standard clinical practice devices, analyzing a large and diverse population. Additionally, the application will facilitate big data collection to enhance the algorithm's performance in measuring hemoglobin, glycated hemoglobin and total cholesterol.

Methods: To achieve the objectives of this study, 3.000 subjects will be consecutively enrolled from June 2024 to December 2024. In all patients personal data collection and medical condition and treatment overview will be recorded. The "By Face" method for rPPG vital signs data collection involves recording subjects' faces using the front camera of mobile devices (iOS and Android) for approximately 1.5 minutes. Simultaneously, vital signs will be continuously collected for about 1.5 minutes using the reference devices alongside data collected via the comestai application; biochemical results will be also recorded.

Results: The accuracy of the app measurements compared to the reference devices and standard tests will be assessed for all parameters. Confidence intervals will be calculated using the bootstrap method. The proposed approach's effectiveness was evaluated using various quality criteria, including the mean error (ME), standard deviation (STD), mean absolute error (MAE), root mean square error (RMSE), and mean absolute percentage error (MAPE). The correlation between measurements obtained using the app and those from reference devices and standard tests will be evaluated using the Pearson correlation coefficient. The agreement between the two sets of measurements (app vs reference devices/standard tests) will be represented using Bland-Altman plots. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and likelihood ratios were calculated to determine the ability of the new application to accurately measure vital signs.

Conclusions: our study will enhance and support the accuracy data on vital sign detection through PPG, also introducing measurements of biochemical risk indicators. The evaluation of a large population will allow for continuous improvement in the

performance and accuracy of artificial intelligence algorithms, reducing errors. Expanding research opportunities to evaluate mHealth solutions as effective and dependable screening tools is useful for preventive strategies. App solutions, such as comestai, may present new opportunities and challenges related to technology use in the healthcare sector, offering insights and guiding future research directions. Clinical Trial: The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756).

(JMIR Preprints 09/08/2024:65229)

DOI: <https://doi.org/10.2196/preprints.65229>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

✓ **No, I do not wish to publish my submitted manuscript as a preprint.**

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <https://preprints.jmir.org/preprint/65229>

No. Please do not make my accepted manuscript PDF available to anyone. I understand that if I later pay to participate in <https://preprints.jmir.org/preprint/65229>

Original Manuscript

Vital signs and biochemical data collection via “comestai” mHealth App, using non-contact photoplethysmography. Protocol for a clinical trial.

Gianvincenzo Zuccotti^{1,2}, Paolo Osvaldo Agnelli³, Lucia Labati², Erika Cordaro², Davide Braghieri², Simone Balconi², Marco Xodo³, Fabrizio Losurdo⁴, Cesare Celeste Federico Berra⁵, Roberto Franco Enrico Pedretti⁵, Paolo Fiorina^{4,6}, Sergio De Pasquale³, Valeria Calcaterra^{2,7}

¹Department of Biomedical and Clinical Science, University of Milano, Milano, Italy.

²Pediatric Department, Buzzi Children's Hospital, Milano, Italy.

³Come stai S.p.A, Milano, Italy

⁴Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milano, Italy

⁵IRCCS MultiMedica, Milano, Italy

⁶International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science, University of Milano, Milano, Italy.

⁷Pediatric and Adolescent Unit, Department of Internal Medicine, University of Pavia, Pavia, Italy

Corresponding author:

Prof. Gianvincenzo Zuccotti

Pediatric Department, Buzzi Children's Hospital and University of Milano

Via Castelvetro 32, 20154 Milano, Italy

gianvincenzo.zuccotti@unimi.it

Abstract

Background Early detection of changes in vital signs typically correlates with faster identification of changes in the patient's health status and the escalation of care if necessary. Alterations in vital signs preceding clinical deterioration are well documented, and the early identification of preventable outcomes is crucial for timely intervention.

Objective In this study, vital parameters (heart rate, respiratory rate, oxygen saturation, and blood pressure) will be measured using the 'comestai' application to confirm the accuracy of photoplethysmography (PPG) methods compared to standard clinical practice devices, analyzing a large and diverse population. Additionally, the application will facilitate big data collection to enhance the algorithm's performance in measuring hemoglobin, glycated hemoglobin and total cholesterol.

Methods: To achieve the objectives of this study, 3,000 subjects will be consecutively enrolled. In all patients personal data collection and medical condition and treatment overview will be recorded. The "By Face" method for rPPG vital signs data collection involves recording subjects' faces using the front camera of mobile devices (iOS and Android) for approximately 1.5 minutes. Simultaneously, vital signs will be continuously collected for about 1.5 minutes using the reference devices alongside data collected via the comestai application; biochemical results will be also recorded. The accuracy of the app measurements compared to the reference devices and standard tests will be assessed for all parameters. Confidence intervals will be calculated using the bootstrap method. The proposed approach's effectiveness was evaluated using various quality criteria, including the mean error, standard deviation, mean absolute error, root mean square error, and mean absolute percentage error. The correlation between measurements obtained using the app and those from reference devices and standard tests will be evaluated using the Pearson correlation coefficient. The agreement between the two sets of measurements (app vs reference devices/standard tests) will be represented using Bland-Altman plots. Sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and likelihood ratios were calculated to determine the ability of the new application to accurately measure vital signs.

Results: Data collection began in June 2024. As of November 22, 2024, we have recruited 736 subjects. Outcomes of the study are expected at the end of 2025. The analysis plan involves verifying and validating the parameters collected from mobile devices via the app, reference devices, and pre-scheduled blood tests, along with patient demographic data.

Conclusions: our study will enhance and support the accuracy data on vital sign detection through PPG, also introducing measurements of biochemical risk indicators. The evaluation of a large population will allow for continuous improvement in the performance and accuracy of artificial intelligence algorithms, reducing errors. Expanding research opportunities to evaluate mHealth solutions as effective and dependable screening tools is useful for preventive strategies. App solutions, such as comestai, may present new opportunities and challenges related to technology use in the healthcare sector, offering insights and guiding future research directions.

Trial Registration: The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756).

Key words: vital signs, biochemical data, mHealth, application, photoplethysmography



Introduction

In recent decades, there has been an increasing focus on self-monitoring applications in primary care, which, with the advent of new technologies, have become more convenient and accessible for patients [1-3].

The use of mobile health (mHealth) apps is undeniably a valuable tool for enabling self-monitoring and healthcare interventions [4,5]. Specifically, the advancement of non-contact techniques for monitoring human vital signs holds significant potential to enhance patient care across various settings [6-7].

By enabling easier and more convenient monitoring, these techniques can mitigate serious health issues and improve patient outcomes, particularly benefiting individuals who cannot or prefer not to visit traditional healthcare settings. Vital signs are objective measures of the essential physiological functions of a living organism and they are the critical starting steps in any clinical evaluation.

Early detection of changes in vital signs typically correlates with faster identification of changes in the patient's health status and the escalation of care if necessary [8]. Alterations in vital signs preceding clinical deterioration are well documented, and the early identification of preventable outcomes is crucial for timely intervention [8]. It is logical that the more frequently vital signs are measured, the quicker clinical deterioration can be detected.

The application named "comestai" is a non-invasive and easy-to-use tool that enables the measurement of different vital parameter. The app allows users to simultaneously measure vital parameters such as Heart Rate (HR), Respiratory Rate (RR), Oxygen Saturation (SpO2), and Blood Pressure (BP), Hemoglobin (Hb), and Glycated Hemoglobin (HbA1c) using the photoplethysmographic method with the front camera of a mobile device.

Photoplethysmography (PPG) is a practical method for non-contact vital sign measurement using a Red-Green-Blue (RGB) camera that has been recently introduced [6,9]. PPG utilizes a transducer that emits infrared light from a LED into the dermis. The adjacent photodetector measures the backscattered light, which is then represented as a line tracing. The intensity of the backscattered light changes with the volume of red blood cells in the dermal capillaries [9]. PPG captures color change signals collected from various regions of the face, correlating the estimated magnitudes of red cell aggregation influenced by blood perfusion with the reflected light intensity in each region. By comparing variations in the averaged color signals, the camera-based signal-to-noise ratio (SNR) estimates are enhanced.

As reported by [10,11], PPG has shown promising results in measuring vital signs and could be a valuable tool for the early detection and screening of cardiovascular, respiratory, and metabolic conditions. These interventions could be crucial in combating noncommunicable chronic diseases (NCDs) [12]. Moreover, literature data on the use of PPG for vital sign detection usually refer to controlled clinical settings. Larger, more diverse populations need to be included to ensure accuracy across various demographics and health conditions [10,12,13].

In this study, vital parameters will be measured using the 'comestai' application to confirm the accuracy of PPG methods compared to standard clinical practice devices, analyzing a large and diverse population.

Additionally, the application will facilitate big data collection to enhance the algorithm's performance in measuring Hb, HbA1c, and total cholesterol. The results will be useful to determine whether this user-friendly mobile application achieves adequate accuracy and can be adopted to enhance self-monitoring of health status and detect early health deterioration. A secondary result will be the collecting of raw data that can be used to train the algorithm to detect other vitals.

Methods

Ethical Considerations

The study was approved by the Ethics Committee (Comitato Etico Territoriale Lombardia 1, Milano, Italy, approval code: CET 98-2024). The study will be conducted according to the Declaration of Helsinki guidelines, to International Guidelines and to current Clinical Trial laws.

All participants will give their written consent after being fully informed about the study. For individuals under 18 years both legal guardians' written consent and assent by adolescents themselves will be collected.

Data will be collected and stored securely to maintain confidentiality, with only authorized personnel having access to identifiable information.

The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756). If modifications in the original protocol will be required, additional amendments will be demanded to the Ethic Committee. In this scenario, the approved related information will be updated on clinicaltrial.gov.

To ensure a greater scientific rigor, the authors followed the SPIRIT guidelines for study protocols reporting (Multimedia Appendix file 1).

Recruitment

To achieve the objectives of this study, 3.000 subjects will be recruited from the outpatient clinic of ASST-Fatebenefratelli-Sacco, Buzzi Children's Hospital and IRCCS MultiMedica in Milan, Italy. **All subjects who meet the inclusion criteria and provide consent to participate will be enrolled consecutively. Recruitment will take place from June 2024 to September 2025.**

Participants eligible for inclusion in the study must meet the following criteria:

Inclusion Criteria:

1. Must demonstrate the ability to comprehend and provide written informed consent.
2. Male or female subjects aged ≥ 16 and ≤ 65 years.
3. Must be willing and able to adhere to study procedures.

Exclusion Criteria: Participants will be excluded if they meet any of the following conditions:

1. Compromised circulation, injury, or physical abnormalities affecting fingers, hands, ears, forehead/skull, or other Regions of Interest (ROI) essential for study testing.
2. Presence of tattoos in the optical path that hinder assessment of necessary ROIs.

3. Severe allergies to standard adhesives, latex, or other materials used in medical sensors for measuring vital signs.
4. Medical conditions that, in the investigator's opinion, prevent the conduct of study assessments.
5. Considered unfit for participation by the investigator.

In addition to the above criteria, 70% of the target population should include adult subjects meeting at least one of the following conditions:

- Pre-diabetes or diabetes with HbA1C levels between 5.7% and 13%:
 - 30% of subjects with HbA1C 5.7-6.4%
 - 30% of subjects with HbA1C >6.4%
- Hypertension with systolic measurements exceeding 130 mmHg:
 - 40% of subjects with systolic BP >130 mmHg
 - 20% of subjects with systolic BP >160 mmHg
- Total cholesterol:
 - 40% of subjects with levels >200 mg/dl and/or **low-density lipoprotein (LDL)** cholesterol >130 mg/dl
- Atrial fibrillation (~1% prevalence)
- Smokers, constituting approximately 20-30% of the study cohort

Family history of diabetes or hypertension will be also investigated.

Written informed consent will be obtained from all participants, and data collection will be performed by a trained research team.

Consent will be requested for the use of the blood sample results (complete blood count, HbA1C, lipid profile, glucose, creatinine). Consenting to view the biochemical data is optional. A subject who chooses not to provide their biochemical results will still be eligible to participate and complete the recordings.

The following procedures and evaluations will be performed during screening to enroll eligible subjects

- Obtain subject consent and, if agrees, additional consent for a blood sample.
- Review eligibility - Assess eligibility as per described in inclusion and exclusion criteria
- Record the subject medical and medication history: each medical problem encountered is classified into the sector of the body involved and for each of these the starting date and the drugs used for treatment are indicated.
- Record subject demographics including date of birth, age, smoking and alcohol drinking habits.
- Record body characteristics including height, weight (body mass index will be calculated as person's weight in kilograms divided by the square of height in meters) and skin tone using the Fitzpatrick scale

- Interview the patient about his feelings in the last two weeks, if he has suffered from problems such as anxiety, nervousness, lack of control, loss of interest in doing things or depression.
- Notation of characterizing aspects such as scars, piercings, beard, glasses, pony or the use of facial products, sunscreen cream or nail polish. Furthermore, a current pregnancy is reported.

The flow protocol of the process is schematized in Figure 1.

Technology

comestai.app is a mobile application that leverages a combination of signal processing and AI technologies, along with a proprietary mathematical backend server, to analyze the skin of the upper cheek region through a smartphone's front camera (iOS and Android).

The comestai app captures video images using signal processing AI technologies and analyzes the data using PPG techniques (Figure 2) [9,14,15,16]. This approach provides real-time measurements of physiological parameters, including SpO₂, HR, PR and RR and biochemical parameters Hb, HbA_{1c}, total cholesterol. Unlike other applications, the application uses a novel technology that extracts ambient light RGB signals from face videos in real-time, eliminating the need for cloud servers or an internet connection.

Equipment for Data Collection

For vital signs data collection using the comestai application, the study staff will use the following mobile phones for rPPG “By Face” measurements:

- Face: iPhone 13 Pro (10 bit) & Samsung Galaxy S21 Ultra
- Two additional phones will be used remotely:
 - One Android phone – Recorder Remote for initiating measurements from a distance.
 - One iPhone – Masimo App for collecting data from the Masimo finger sensor.
- Other necessary equipment includes phone stands (two per measurement room).

In addition to the equipment for vital signs data collection using the comestai application, reference devices will be used to measure the subject's vital signs for comparative purposes.

Vital Signs Data Collection Using the comestai Application and Reference Devices

The study personnel will gather vital signs data in a designated room equipped with the following amenities:

- A table
- A chair with headrest and arm support
- A white wall for subjects to sit against
- Stable Wi-Fi
- Power sockets

- Adequate lighting assessment: if the room lacks sufficient illumination, one Theralite lamp per room will be necessary.

Vital signs data will be gathered using the comestai application through the "By Face" method and with the reference devices detailed in Table 1.

Table 1. Reference Devices for Measuring Vital Signs

Device	Saturation O ₂	Pulse Rate	Respiratory Rate	Blood Pressure
Withings BPM Connect				X
Masimo mightySat Rx	X	X	X	
Polar Verity Sense		X		

Specifically, as reported in Figure 3, the measurement Procedure Flow will be:

- The subject should sit for 2 minutes for stabilization with references connected.
- Baseline distance ~25 cm (closest as possible)
- Measure BP twice (if systolic ± 10 and/or diastolic ± 5 make a third measurement) - waiting one minute in between the two.
- Make 1 recording with each device.
- Measure BP twice (if systolic ± 10 and/or diastolic ± 5 make a third measurement)

The "By Face" method for rPPG vital signs data collection involves recording subjects' faces using the front camera of mobile devices (iOS and Android) for approximately 1.5 minutes.

During "By Face" data collection, subjects will be seated comfortably, facing a screen at approximately 25 cm, with their face fully visible (without wearing masks, hats, or any facial accessories). Subjects are required to maintain stable breathing and minimal movement, and to gaze directly at the camera throughout the data collection process.

Simultaneously, vital signs data (SpO₂, RR, BP, PR) will be continuously collected for about 1.5 minutes using the reference devices alongside data collected via the comestai application.

BP measurements will be taken using the reference devices before and immediately after data collection with the comestai application.

Data Collection and Management

Data from the investigational device will be collected by trained staff members. Vital signs data obtained using the application and reference data will be stored on a secured cloud. To ensure that no information would be stored in the comestai cloud, the application will be activated only when the cell phone is offline. Consequently, the company will not have access to any data collected during the tests.

Additionally, the application will be deleted after use to prevent any data from being uploaded into the system. Data collected using the reference devices, will be stored without any identifiable subject information and will only be identifiable using the subject identification number provided during screening.

The raw data of subjects' vital signs will be locked, encrypted, and accessible only to the Study Center team. Raw data can be processed only after unlocking the files to calculate the final measured results.

The Coordinator Center (Buzzi Children's Hospital) will be responsible for securely storing the data in a locked and secured location. The Endocrinology Unit of ASST-Fatebenefratelli-Sacco and Buzzi Children's Hospital will handle data entry and ensure data quality.

This study will be conducted in compliance with Good Clinical Practice (GCP), including the archiving of essential documents.

No medical decisions will be made based on the data obtained from the comestai application, reference devices, or blood sample results.

Clinical Data Cleaning and Validation

Clinical data for the study will be meticulously organized, easily accessible, and thoroughly cleaned both throughout and after the study concludes (post Data Lock). Activities in clinical data management encompass data collection and entry, tracking electronic Case Report Form (eCRF) usage, database design, data validation, and database locking.

As previously outlined, the eCRF will serve as the primary tool for capturing clinical data. The data fields within the eCRF are clearly defined and maintain consistency throughout. The eCRF is designed to be succinct, intuitive, and user-friendly.

Database edit checks will be conducted to identify discrepancies in the data, which could stem from inconsistent entries, missing data points, range discrepancies, or deviations from the study protocol. Any incomplete discrepancies will be addressed by site investigators. Continuous quality control measures for data processing will be implemented at regular intervals throughout the study duration.

Criteria for Data Collection and Study Interruption

Temporal interruption of vital signs data collection using the application may occur in the following cases:

- Technical issues with the investigational and/or reference devices

The study may be interrupted for the following reasons:

- Breach of subject confidentiality
- Decision by the Principal Investigator (PI) or Institutional Ethics Committee (IEC)

The investigators may also decide to terminate the study early if sufficient data has been collected for algorithm improvement.

Statistical Analysis

Numerical variables will be presented as minimum and maximum values, means, standard deviations (SD), medians, and quartiles. Categorical variables will be presented as absolute and relative frequencies.

The accuracy of the app measurements compared to the reference devices and standard tests will be assessed for all parameters. Confidence intervals will be calculated using the bootstrap method. Participants with abnormal adverse events (defined as 3 standard deviations or more above the mean) and those with invalid reference device values will be excluded from the analysis.

In order to provide a more comprehensive view of the model's performance, the proposed approach's effectiveness was evaluated using various quality criteria, including the mean error (ME), SD, mean absolute error (MAE), root mean square error (RMSE), and mean absolute percentage error (MAPE). The correlation between measurements obtained using the app and those from reference devices and standard tests will be evaluated using the Pearson correlation coefficient. The agreement between the two sets of measurements (app vs. reference devices/standard tests) will be represented using Bland-Altman plots. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and likelihood ratios will be calculated to determine the ability of the new application to accurately measure vital signs.

Sample Size Estimation

Considering the average values of pressure/saturation/heart rate among a general population with a sample of 3000 subjects, there will be a power exceeding 95% for all evaluated parameters in a two-sided test with a *P*-value of 0.05 if the discrepancy between the two measurement methods is as reported in the Table 2.

Table 2. Expected error level of the measurements

Vital	Range	Unit of measurement	Error level
Pulse Rate	50-180	bmp	RMSE ≤ 3
Respiratory Rate	8-30	brpm	RMSE ≤ 3
Blood Pressure Systolic	80-180	mmHg	MAE ≤ 15
Blood Pressure Diastolic	50-120	mmHg	MAE ≤ 10

RMSE= Root mean square error; MAE= Mean absolute error

Known Potential Risks and Benefits of the Investigational Device

Potential Risks

No adverse device effects (ADEs) are expected from the comestai application, and there are no contraindications for its use in the study population. However, unforeseeable risks related to the data collection process may arise.

One such risk is the potential breach of subject confidentiality due to improper data storage. To mitigate this, vital signs data will be securely stored on comestai's cloud. Videos of faces obtained using the "By Face" method will be anonymized, recognized only by the subject identification number assigned during screening.

The raw vital signs data will be locked, encrypted, and accessible solely by the Study Center team. Processing of this data will only occur once the files are unlocked.

Potential Benefits

Participants in this study will not receive direct benefits. However, the data gathered may aid in the advancement of the comestai non-invasive software application for monitoring vital signs. Progress in this area has the potential to enhance patient care quality and reduce labor time and costs within the healthcare system.

Advances in this field may improve the quality of care provided to patients and save labor time and costs for the healthcare system.

Results

Data collection began in June 2024. As of November 22, 2024, we have recruited 736 subjects. Outcomes of the study are expected at the end of 2025. The analysis plan involves verifying and validating the parameters collected from mobile devices via the app, reference devices, and pre-scheduled blood tests, along with patient demographic data.

Discussion

Principal findings

The project aims to report whether this user-friendly mobile application supports a high level of accuracy in monitoring SpO₂, RR, BP, and PR, demonstrating the same reliability in detecting Hb, HbA1c, and total cholesterol. Enhancing algorithm performance and achieving a high level of accuracy will be crucial in assessing whether the app can be adopted to improve self-monitoring of health status. This, in turn, could enhance the screening for early abnormalities in vital signs and biochemical parameters.

Strengths and Limitations

Today's healthcare industry embraces technological innovations to provide better personalized healthcare services to the public [17]. Mobile-based solutions and applications are one such revolutionary and trending innovation that facilitates enhanced patient care management and efficient diagnosis. They are increasingly reliant on wireless technologies as they evolve [17]. Applications of mHealth typically include the use of mobile devices in the collection of health and clinical data, the provision of health information to practitioners, researchers, and patients, the real-time monitoring of patients; vital signs, and the direct delivery of care (via mobile telemedicine).

In an mHealth context, the advancement of non-contact methods to monitor human vital signs holds substantial promise for enhancing patient care across various environments [6].

A recently proposed RGB camera-based method for non-contact vital sign measurement using PPG has

been identified as an interesting tool for recording vital signs. PPG is also employed by the comestai App to assess various vital functions including SpO₂, RR, BP, and PR [10]. Initial research into PPG shows promising outcomes; however, scientific evidence regarding the accuracy and benefits of digital health applications that measure vital signs remains limited and somewhat controversial. Many PPG studies are still susceptible to errors [18-20], with the majority involving only small sample sizes.

In our protocol, we will recruit a large population (3.000 subjects) to ensure accuracy across various demographics and health conditions, including also pathological conditions. The use of a large population will also help reduce errors in the results, improving the reliability of the tool. Thorough analysis and classification of these signals are essential for the development of affordable and user-friendly PPG-based tools across a wide range of applications [10].

While there is an increasing number of articles and research on SpO₂, RR, BP, PR monitoring using PPG, limited number of available publications on advancements related to biochemical parameters estimation are reported [10]. Comestai offers the possibility to monitor Hb, HbA1c and cholesterol concurrently with other parameters, thereby broadening its application possibilities in healthcare services.

Although the protocol included subjects with diseases such as hypertension, pre-diabetes and diabetes, dyslipidemia and atrial fibrillation to assess the tool's accuracy even in the presence of pathological values, conducting the study in a controlled setting can be considered a limitation. Its application in real-life scenarios may present challenges that were not accounted for.

Future Research

As suggested by the World Health Organization (WHO), it is important to disseminate medical procedures and health programs based on mHealth [21]. Mobile apps have become increasingly popular among professionals and individuals involved in the healthcare sector, with a variety of mHealth applications developed to improve healthcare facilities for all kinds of patients [22,23]

Specifically, mobile apps can play a vital role in screening, leading to the early detection of vital sign alterations, which is useful for alerting individuals and their caregivers to access medical care services and design and implement treatment plans. Screening is considered a crucial player in addressing chronic noncommunicable diseases (NCDs), which are responsible for nearly 70% of all deaths worldwide [12,24,25].

According to the WHO [12], NCDs cause 41 million deaths each year. This burden is expected to grow over the next decade, with NCD deaths projected to reach 52 million by 2030. Cardiovascular diseases (CVDs) are the leading cause of NCD deaths, accounting for 17.9 million fatalities annually. They are followed by chronic respiratory diseases (4.1 million) and diabetes (2.0 million, including kidney disease deaths linked to diabetes). Early detection and screening are vital strategies in combating NCDs. Disease screening detects diseases early, often before symptoms appear, through tests, examinations, or other rapid procedures [26]. This early detection enables effective prevention or treatment of identified diseases through timely medical intervention for those at risk [27].

Despite screening being recognized as the gateway to care, routine NCD screening at community and health facilities remains challenging due to limited capacity within health systems. A screening tool must be clearly simple, valid, reliable, quick to administer, cost-effective, and user-friendly [23]. According to reports, PPG wearables have significant potential for estimating the risk of CVDs [28], predicting suspected sleep apnea [29,30], and helping in the clinical diagnosis of hypertension [31] and diabetes. This potential can be harnessed through app solutions.

Recent reviews have assessed the role of apps in aiding self-management and transition among chronically ill young people, enhancing the lifestyles of chronic patients, and improving lifestyle in NCDs [32]. As reported by Moses, regardless of a country's economic status, there has been a rise in mobile cellular subscriptions per hundred people in developing nations [27], mobile App solutions may provide equitable healthcare solutions without barriers.

Conclusion

Our study will enhance and support the accuracy data on vital sign detection through PPG, also introducing measurements of biochemical risk indicators. The evaluation of a large population will allow for continuous improvement in the performance and accuracy of artificial intelligence algorithms, reducing errors. Expanding research opportunities to evaluate mHealth solutions as effective and dependable screening tools is useful for preventive strategies, reducing the burden of NCDs [27]. App solutions, such as comestai, may present new opportunities and challenges related to technology use in the healthcare sector, offering insights and guiding future research directions.

Acknowledgments

The authors thank Come Stai S.p.A. for providing the Comestai app and all materials used for the protocol free of charge for the entire duration of the project. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Data availability

The data that will support the findings of this study will be derived from subjects record data. All data generated or analyzed during this study will be included in the published article and its supplementary information files

Authors' Contributions

Conceptualization: GV, POA, VC

Investigation LL, EC, DB, SB, FL, CCCFB, RFEP, MX

Methodology: GV, POA, LL, EC, DB, SB, FL, MX, CCCFB, RFEP, PF, SDP, VC

Project administration: GV, VC

Supervision: GV, POA, VC

Writing – original draft: LL, EC, DB, SB, FL, VC

Writing – review and editing: GV, POA, PF, SDP, VC

Competing interests

P.O.A. and S.D.P are co-founders of come stai S.p.A

Multimedia Appendix 1

SPIRIT checklist

Abbreviations

App=application

BP=Blood Pressure

CVDs=cardiovascular diseases

HR=Heart Rate

MAE=mean absolute error

MAPE=mean absolute percentage error

ME=mean error

NCDs=noncommunicable diseases

PP=photoplethysmography

RMSE=root mean square error

RR=Respiratory Rate

SpO2=Oxygen Saturation

STD=standard deviation

WHO=World Health Organization

References

1. Huygens MW, Swinkels IC, de Jong JD, Heijmans MJ, Friele RD, van Schayck OC, de Witte LP. Self-monitoring of health data by patients with a chronic disease: does disease controllability matter? *BMC Fam Pract*. 2017 Mar 20;18(1):40. doi: 10.1186/s12875-017-0615-3. PMID: 28320330; PMCID: PMC5360032.
2. Senbekov M, Saliev T, Bukeyeva Z, Almagbayeva A, Zhanaliyeva M, Aitenova N, Toishibekov Y, Fakhradiyev I. The Recent Progress and Applications of Digital Technologies in Healthcare: A Review. *Int J Telemed Appl*. 2020 Dec 3;2020:8830200. doi: 10.1155/2020/8830200. PMID: 33343657; PMCID: PMC7732404.
3. Amjad A, Kordel P, Fernandes G. A Review on Innovation in Healthcare Sector (Telehealth) through Artificial Intelligence. *Sustainability* 2023, 15,6655. doi:10.3390/su15086655.
4. Wang H, Ho AF, Wiener RC, Sambamoorthi U. The Association of Mobile Health Applications with Self-Management Behaviors among Adults with Chronic Conditions in the United States. *Int J Environ Res Public Health*. 2021 Sep 30;18(19):10351. doi: 10.3390/ijerph181910351. PMID: 34639651; PMCID: PMC8507726.
5. Mahmood A, Kedia S, Wyant DK, Ahn S, Bhuyan SS. Use of mobile health applications for health-promoting behavior among individuals with chronic medical conditions. *Digit Health*. 2019 Oct 10;5:2055207619882181. doi: 10.1177/2055207619882181. PMID: 31656632; PMCID: PMC6791047.
6. Saikevičius L, Raudonis V, Dervinis G, Baranauskas V. Non-Contact Vision-Based Techniques of Vital Sign Monitoring: Systematic Review. *Sensors (Basel)*. 2024 Jun 19;24(12):3963. doi: 10.3390/s24123963. PMID: 38931747; PMCID: PMC11207835.
7. Hall T, Lie DYC, Nguyen TQ, Mayeda JC, Lie PE, Lopez J, Banister RE. Non-Contact Sensor for Long-Term Continuous Vital Signs Monitoring: A Review on Intelligent Phased-Array Doppler Sensor Design. *Sensors (Basel)*. 2017 Nov 15;17(11):2632. doi: 10.3390/s17112632. PMID: 29140281; PMCID: PMC5713025.
8. Brekke IJ, Puntervoll LH, Pedersen PB, Kellett J, Brabrand M. The value of vital sign trends in predicting and monitoring clinical deterioration: A systematic review. *PLoS One*. 2019 Jan 15;14(1):e0210875. doi: 10.1371/journal.pone.0210875. PMID: 30645637; PMCID: PMC6333367.
9. Loh HW, Xu S, Faust O, Ooi CP, Barua PD, Chakraborty S, Tan RS, Molinari F, Acharya UR. Application of photoplethysmography signals for healthcare systems: An in-depth review. *Comput Methods Programs Biomed*. 2022 Apr;216:106677. doi: 10.1016/j.cmpb.2022.106677. Epub 2022 Feb 1. PMID: 35139459.
10. Almarshad MA, Islam MS, Al-Ahmadi S, BaHamman AS. Diagnostic Features and Potential Applications of PPG Signal in Healthcare: A Systematic Review. *Healthcare (Basel)*. 2022 Mar 16;10(3):547. doi: 10.3390/healthcare10030547. PMID: 35327025; PMCID: PMC8950880.


11. Charlton PH, Allen J, Bailón R, Baker S, Behar JA, Chen F, Clifford GD, Clifton DA, Davies HJ, Ding C, Ding X, Dunn J, Elgendi M, Ferdoushi M, Franklin D, Gil E, Hassan MF, Hernesniemi J, Hu X, Ji N, Khan Y, Kontaxis S, Korhonen I, Kyriacou PA, Laguna P, Lázaro J, Lee C, Levy J, Li Y, Liu C, Liu J, Lu L, Mandic DP, Marozas V, Mejía-Mejía E, Mukkamala R, Nitzan M, Pereira T, Poon CCY, Ramella-Roman JC, Saarinen H, Shandhi MMH, Shin H, Stansby G, Tamura T, Vehkaoja A, Wang WK, Zhang YT, Zhao N, Zheng D, Zhu T. The 2023 wearable photoplethysmography roadmap. *Physiol Meas*. 2023 Nov 29;44(11):111001. doi: 10.1088/1361-6579/acead2. PMID: 37494945; PMCID: PMC10686289.
12. https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1, doi: [10.4103/ijpvm.IJPVM_487_20](https://doi.org/10.4103/ijpvm.IJPVM_487_20)
13. Kim KB, Baek HJ. Photoplethysmography in Wearable Devices: A Comprehensive Review of Technological Advances, Current Challenges, and Future Directions. *Electronics* 2023, 12, 2923. doi: 103390/electronics12132923.
14. Castellano Ontiveros R, Elgendi M, Menon C. A machine learning-based approach for constructing remote photoplethysmogram signals from video cameras. *Commun Med (Lond)*. 2024 Jun 7;4(1):109. doi: 10.1038/s43856-024-00519-6. PMID: 38849495; PMCID: PMC11161609.
15. Gayathri Priyadarshini R, Kalimuthu M, Nikesh S, Bhuvaneshwari M. Review of PPG signal using Machine Learning Algorithms for Blood Pressure and Glucose Estimation. *IOP Conf. Ser.: Mater. Sci. Eng*. 2021; 1084. doi 10.1088/1757-899X/1084/1/012031
16. Esgalhado F, Fernandes B, Vassilenko V, Batista A, Russo S. The Application of Deep Learning Algorithms for PPG Signal Processing and Classification. *Computers*. 2021; 10(12):158. <https://doi.org/10.3390/computers10120158>
17. Stoumpos AI, Kitsios F, Talias MA. Digital Transformation in Healthcare: Technology Acceptance and Its Applications. *Int J Environ Res Public Health*. 2023;20(4):3407. Published 2023 Feb 15. doi:10.3390/ijerph20043407
18. Challoner AV, Ramsay CA. A photoelectric plethysmograph for the measurement of cutaneous blood flow. *Phys Med Biol*. 1974 May;19(3):317-28. doi: 10.1088/0031-9155/19/3/003. PMID: 4445210.
19. Ruiz-Rodríguez JC, Ruiz-Sanmartín A, Ribas V, Caballero J, García-Roche A, Riera J, Nuvials X, de Nadal M, de Sola-Morales O, Serra J, Rello J. Innovative continuous non-invasive cuffless blood pressure monitoring based on photoplethysmography technology. *Intensive Care Med*. 2013 Sep;39(9):1618-25. doi: 10.1007/s00134-013-2964-2. Epub 2013 Jun 6. PMID: 23740275.
20. Nitzan M, Adar Y, Hoffman E, Shalom E, Engelberg S, Ben-Dov IZ, Bursztyn M. Comparison of systolic blood pressure values obtained by photoplethysmography and by Korotkoff sounds. *Sensors (Basel)*. 2013 Oct 31;13(11):14797-812. doi: 10.3390/s131114797. PMID: 24184918; PMCID: PMC3871084.
21. https://www.afro.who.int/sites/default/files/2020-11/WHO_Strategy_on_research_for_health.pdf

22. Kernebeck S, Busse TS, Böttcher MD, Weitz J, Ehlers J, Bork U. Impact of mobile health and medical applications on clinical practice in gastroenterology. *World J Gastroenterol*. 2020 Aug 7;26(29):4182-4197. doi: 10.3748/wjg.v26.i29.4182. PMID: 32848328; PMCID: PMC7422538.
23. Vijayasarathi A, Kharkar R, Salamon N. Strategies for Patient-Centered Communication in the Digital Age. *Curr Probl Diagn Radiol*. 2019 May-Jun;48(3):210-215. doi: 10.1067/j.cpradiol.2018.05.004. Epub 2018 Jun 1. PMID: 30075879.
24. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
25. Hadian M, Mozafari MR, Mazaheri E, Jabbari A. Challenges of the Health System in Preventing Non-Communicable Diseases; Systematized Review. *Int J Prev Med*. 2021 Jun 25;12:71. doi: 10.4103/ijpvm.IJPVM_487_20. PMID: 34447513; PMCID: PMC8356955.
26. Principles and practice of screening for disease. *J R Coll Gen Pract*. 1968;16(4):318.
27. Moses JC, Adibi S, Wickramasinghe N, Nguyen L, Angelova M, Islam SMS. Smartphone as a Disease Screening Tool: A Systematic Review. *Sensors (Basel)*. 2022 May 16;22(10):3787. doi: 10.3390/s22103787. PMID: 35632195; PMCID: PMC9145643.
28. Clarenbach CF, Stoewhas AC, van Gestel AJ, Latshang TD, Lo Cascio CM, Bloch KE, Kohler M. Comparison of photoplethysmographic and arterial tonometry-derived indices of arterial stiffness. *Hypertens Res*. 2012 Feb;35(2):228-33. doi: 10.1038/hr.2011.168. Epub 2011 Oct 13. PMID: 21993214.
29. Korkalainen H, Aakko J, Duce B, Kainulainen S, Leino A, Nikkonen S, Afara IO, Myllymaa S, Töyräs J, Leppänen T. Deep learning enables sleep staging from photoplethysmogram for patients with suspected sleep apnea. *Sleep*. 2020 Nov 12;43(11):zsaa098. doi: 10.1093/sleep/zsaa098. PMID: 32436942; PMCID: PMC7658638.
30. Karmakar C, Khandoker A, Penzel T, Schöbel C, Palaniswami M. Detection of respiratory arousals using photoplethysmography (PPG) signal in sleep apnea patients. *IEEE J Biomed Health Inform*. 2014 May;18(3):1065-73. doi: 10.1109/JBHI.2013.2282338. Epub 2013 Sep 23. PMID: 24108482.
31. Ishbulatov YM, Karavaev AS, Kiselev AR, Simonyan MA, Prokhorov MD, Ponomarenko VI, Mironov SA, Gridnev VI, Bezruchko BP, Shvartz VA. Mathematical modeling of the cardiovascular autonomic control in healthy subjects during a passive head-up tilt test. *Sci Rep*. 2020 Oct 5;10(1):16525. doi: 10.1038/s41598-020-71532-7. PMID: 33020530; PMCID: PMC7536219.
32. Virella Pérez YI, Medlow S, Ho J, Steinbeck K. Mobile and Web-Based Apps That Support Self-Management and Transition in Young People With Chronic Illness: Systematic Review. *J Med Internet Res*. 2019 Nov 20;21(11):e13579. doi: 10.2196/13579. PMID: 31746773; PMCID: PMC6893564.


Supplementary Files

Figures

Process flow protocol.



Remote Photoplethysmography from Facial Videos.



Measurement Procedure Flow.



CONSORT (or other) checklists

SPIRIT Checklist.

URL: <http://asset.jmir.pub/assets/d2481a8ff025ecf2e817ba33994be2a1.pdf>

